How Long Will It Take to Launch an Effective Helicobacter pylori Vaccine for Humans?

References

• Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1(8336):1273–1275.
   PubMed Web of Science ®Google Scholar
• Marshall B, Royce H, Annear D, et al. Original isolation of Campylobacter pyloridis from human gastric mucosa. Microbios Lett. 1984;25(98):83–88.
   Google Scholar
• Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22(2):283–297. doi:10.1093/oxfordjournals.epirev.a018040
   PubMed Web of Science ®Google Scholar
• Maleki Kakelar H, Barzegari A, Dehghani J, et al. Pathogenicity of Helicobacter pylori in cancer development and impacts of vaccination. Gastric Cancer. 2019;22(1):23–36. doi:10.1007/s10120-018-0867-1
   PubMed Web of Science ®Google Scholar
• Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–429. doi:10.1053/j.gastro.2017.04.022
   PubMed Web of Science ®Google Scholar
• Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868–876. doi:10.1111/apt.14561
   PubMed Web of Science ®Google Scholar
• Zagari RM, Frazzoni L, Marasco G, Fuccio L, Bazzoli F. Treatment of Helicobacter pylori infection: a clinical practice update. Minerva Med. 2021;112(2):281–287. doi:10.23736/S0026-4806.20.06810-X
   PubMed Web of Science ®Google Scholar
• Lu C, Sang J, He H, et al. Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis. Sci Rep. 2016;6:23522. doi:10.1038/srep23522
   PubMed Web of Science ®Google Scholar
• Goderska K, Agudo Pena S, Alarcon T. Helicobacter pylori treatment: antibiotics or probiotics. Appl Microbiol Biotechnol. 2018;102(1):1–7. doi:10.1007/s00253-017-8535-7
   PubMed Web of Science ®Google Scholar
• Lee YC, Dore MP, Graham DY. Diagnosis and treatment of Helicobacter pylori infection. Annu Rev Med. 2022;73:183–195. doi:10.1146/annurev-med-042220-020814
   PubMed Web of Science ®Google Scholar
• Pallen MJ, Clayton CL. Vaccination against Helicobacter pylori urease. Lancet. 1990;336(8708):186–187. doi:10.1016/0140-6736(90)91716-N
   PubMed Web of Science ®Google Scholar
• Czinn SJ, Nedrud JG. Oral immunization against Helicobacter pylori. Infect Immun. 1991;59(7):2359–2363. doi:10.1128/iai.59.7.2359-2363.1991
   PubMed Web of Science ®Google Scholar
• Czinn SJ, Cai A, Nedrud JG. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine. 1993;11(6):637–642. doi:10.1016/0264-410X(93)90309-L
   PubMed Web of Science ®Google Scholar
• Kreiss C, Buclin T, Cosma M, Corthésy-Theulaz I, Michetti P. Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection. Lancet. 1996;347(9015):1630–1631. doi:10.1016/S0140-6736(96)91119-8
   PubMed Web of Science ®Google Scholar
• Michetti P, Kreiss C, Kotloff KL, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology. 1999;116(4):804–812. doi:10.1016/S0016-5085(99)70063-6
   PubMed Web of Science ®Google Scholar
• DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine. 1999;18(5–6):449–459. doi:10.1016/S0264-410X(99)00246-7
   PubMed Web of Science ®Google Scholar
• Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun. 2000;68(4):2135–2141. doi:10.1128/IAI.68.4.2135-2141.2000
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun. 2001;69(6):3581–3590. doi:10.1128/IAI.69.6.3581-3590.2001
   PubMed Web of Science ®Google Scholar
• Bumann D, Metzger WG, Mansouri E, et al. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine. 2001;20(5–6):845–852. doi:10.1016/S0264-410X(01)00391-7
   PubMed Web of Science ®Google Scholar
• Sougioultzis S, Lee CK, Alsahli M, et al. Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine. 2002;21(3–4):194–201. doi:10.1016/S0264-410X(02)00467-X
   PubMed Web of Science ®Google Scholar
• Banerjee S, Medina-Fatimi A, Nichols R, et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut. 2002;51(5):634–640. doi:10.1136/gut.51.5.634
   PubMed Web of Science ®Google Scholar
• Metzger WG, Mansouri E, Kronawitter M, et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine. 2004;22(17–18):2273–2277. doi:10.1016/j.vaccine.2003.11.020
   PubMed Web of Science ®Google Scholar
• Aebischer T, Bumann D, Epple HJ, et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut. 2008;57(8):1065–1072. doi:10.1136/gut.2007.145839
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Schultze V, Rosenkranz B, et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a Phase I study. Gastroenterology. 2008;135(3):787–795. doi:10.1053/j.gastro.2008.05.054
   PubMed Web of Science ®Google Scholar
• Zeng M, Mao XH, Li JX, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2015;386(10002):1457–1464. doi:10.1016/S0140-6736(15)60310-5
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Selgrad M, Wex T, et al. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled Phase 1/2 study. Lancet Gastroenterol Hepatol. 2018;3(10):698–707. doi:10.1016/S2468-1253(18)30125-0
   PubMed Web of Science ®Google Scholar
• Ha NC, Oh ST, Sung JY, Cha KA, Lee MH, Oh BH. Supramolecular assembly and acid resistance of Helicobacter pylori urease. Nat Struct Biol. 2001;8(6):505–509. doi:10.1038/88563
   PubMedGoogle Scholar
• Mayo K, Held M, Wadström T, Mégraud F. Helicobacter pylori-human polymorphonuclear leucocyte interaction in the presence of ammonia. Eur J Gastroenterol Hepatol. 1997;9(5):457–461. doi:10.1097/00042737-199705000-00009
   PubMed Web of Science ®Google Scholar
• Suzuki M, Miura S, Suematsu M, et al. Helicobacter pylori-associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury. Am J Physiol. 1992;263(5 Pt 1):G719–725. doi:10.1152/ajpgi.1992.263.5.G719
   PubMedGoogle Scholar
• Lytton SD, Fischer W, Nagel W, Haas R, Beck FX. Production of ammonium by Helicobacter pylori mediates occludin processing and disruption of tight junctions in Caco-2 cells. Microbiology. 2005;151(Pt 10):3267–3276. doi:10.1099/mic.0.28049-0
   PubMedGoogle Scholar
• Wroblewski LE, Shen L, Ogden S, et al. Helicobacter pylori dysregulation of gastric epithelial tight junctions by urease-mediated myosin II activation. Gastroenterology. 2009;136(1):236–246. doi:10.1053/j.gastro.2008.10.011
   PubMed Web of Science ®Google Scholar
• Kuwahara H, Miyamoto Y, Akaike T, et al. Helicobacter pylori urease suppresses bactericidal activity of peroxynitrite via carbon dioxide production. Infect Immun. 2000;68(8):4378–4383. doi:10.1128/IAI.68.8.4378-4383.2000
   PubMed Web of Science ®Google Scholar
• Schoep TD, Fulurija A, Good F, et al. Surface properties of Helicobacter pylori urease complex are essential for persistence. PLoS One. 2010;5(11):e15042. doi:10.1371/journal.pone.0015042
   PubMed Web of Science ®Google Scholar
• Scott DR, Marcus EA, Wen Y, Singh S, Feng J, Sachs G. Cytoplasmic histidine kinase (HP0244)-regulated assembly of urease with UreI, a channel for urea and its metabolites, CO2, NH3, and NH4(+), is necessary for acid survival of Helicobacter pylori. J Bacteriol. 2010;192(1):94–103. doi:10.1128/JB.00848-09
   PubMed Web of Science ®Google Scholar
• Nasr-Esfahani M, Doosti A, Sazegar H. Evaluation of the immune response against Helicobacter pylori; in infused BALB/c mice by pcDNA3.1(+)-ureA. Folia Med (Plovdiv). 2020;62(1):37–45. doi:10.3897/folmed.62.e47932
   PubMedGoogle Scholar
• Liu PF, Wang Y, Ulrich RG, et al. Leaf-encapsulated vaccines: agroinfiltration and transient expression of the antigen staphylococcal endotoxin B in radish leaves. J Immunol Res. 2018;2018:3710961. doi:10.1155/2018/3710961
   PubMed Web of Science ®Google Scholar
• Leunk RD, Johnson PT, David BC, Kraft WG, Morgan DR. Cytotoxic activity in broth-culture filtrates of Campylobacter pylori. J Med Microbiol. 1988;26(2):93–99. doi:10.1099/00222615-26-2-93
   PubMed Web of Science ®Google Scholar
• Foegeding NJ, Caston RR, McClain MS, Ohi MD, Cover TL. An overview of Helicobacter pylori VacA toxin biology. Toxins. 2016;8(6). doi:10.3390/toxins8060173
   PubMed Web of Science ®Google Scholar
• Chauhan N, Tay ACY, Marshall BJ, Jain U. Helicobacter pylori VacA, a distinct toxin exerts diverse functionalities in numerous cells: an overview. Helicobacter. 2019;24(1):e12544. doi:10.1111/hel.12544
   PubMed Web of Science ®Google Scholar
• Guo L, Hong D, Wang S, et al. Therapeutic protection against H. pylori infection in Mongolian gerbils by oral immunization with a tetravalent epitope-based vaccine with polysaccharide adjuvant. Front Immunol. 2019;10:1185. doi:10.3389/fimmu.2019.01185
   PubMed Web of Science ®Google Scholar
• Censini S, Lange C, Xiang Z, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A. 1996;93(25):14648–14653. doi:10.1073/pnas.93.25.14648
   PubMed Web of Science ®Google Scholar
• Tummuru MK, Cover TL, Blaser MJ. Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production. Infect Immun. 1993;61(5):1799–1809. doi:10.1128/iai.61.5.1799-1809.1993
   PubMed Web of Science ®Google Scholar
• Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S A. 1993;90(12):5791–5795. doi:10.1073/pnas.90.12.5791
   PubMed Web of Science ®Google Scholar
• Hatakeyama M, Higashi H. Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis. Cancer Sci. 2005;96(12):835–843. doi:10.1111/j.1349-7006.2005.00130.x
   PubMed Web of Science ®Google Scholar
• Esmaeili D, Mobarez A, Salmanian A, Zavaran Hosseini A, Doust H. Immune responses of conserved 32 KD fragment from N-terminal of H. pylori cagA gene. J Pure Appl Microbio. 2010;4:117–123.
   Web of Science ®Google Scholar
• Shapouri Moghaddam A, Mansouri S, Neshani A, et al. Construction, cloning, and expression of CagA recombinant protein of Helicobacter pylori. Avicenna J Med Biotechnol. 2020;12(2):135–138.
   PubMedGoogle Scholar
• Mohabatimobarez A, Salmanian AH, Hosseini AZ, Esmaeili D. Clearance of Helicobacter pylori with formulation rCagA and LPS in a mouse model. Gene Reports. 2020;19:100588. doi:10.1016/j.genrep.2020.100588
   Web of Science ®Google Scholar
• Paydarnia N, Mansoori B, Esmaeili D, et al. Helicobacter pylori recombinant CagA regulates Th1/Th2 balance in a BALB/c murine model. Adv Pharm Bull. 2020;10(2):264–270. doi:10.34172/apb.2020.031
   PubMed Web of Science ®Google Scholar
• Kutter S, Buhrdorf R, Haas J, Schneider-Brachert W, Haas R, Fischer W. Protein subassemblies of the Helicobacter pylori Cag type IV secretion system revealed by localization and interaction studies. J Bacteriol. 2008;190(6):2161–2171. doi:10.1128/JB.01341-07
   PubMed Web of Science ®Google Scholar
• Kumari R, Shariq M, Sharma S, Kumar A, Mukhopadhyay G. CagW, a VirB6 homologue interacts with Cag-type IV secretion system substrate CagA in Helicobacter pylori. Biochem Biophys Res Commun. 2019;515(4):712–718. doi:10.1016/j.bbrc.2019.06.013
   PubMed Web of Science ®Google Scholar
• Chehelgerdi M, Doosti A. Effect of the cagW-based gene vaccine on the immunologic properties of BALB/c mouse: an efficient candidate for Helicobacter pylori DNA vaccine. J Nanobiotechnology. 2020;18(1):63. doi:10.1186/s12951-020-00618-1
   PubMed Web of Science ®Google Scholar
• Kwok T, Zabler D, Urman S, et al. Helicobacter exploits integrin for type IV secretion and kinase activation. Nature. 2007;449(7164):862–866. doi:10.1038/nature06187
   PubMed Web of Science ®Google Scholar
• Tegtmeyer N, Hartig R, Delahay RM, et al. A small fibronectin-mimicking protein from bacteria induces cell spreading and focal adhesion formation. J Biol Chem. 2010;285(30):23515–23526. doi:10.1074/jbc.M109.096214
   PubMed Web of Science ®Google Scholar
• Aliramaei MR, Khorasgani MR, Rahmani MR, Zarkesh Esfahani SH, Emamzadeh R. Expression of Helicobacter pylori CagL gene in Lactococcus lactis MG1363 and evaluation of its immunogenicity as an oral vaccine in mice. Microb Pathog. 2019;142:103926. doi:10.1016/j.micpath.2019.103926
   PubMed Web of Science ®Google Scholar
• Hazell SL, Evans DJ, Graham DY. Helicobacter pylori catalase. J Gen Microbiol. 1991;137(1):57–61. doi:10.1099/00221287-137-1-57
   PubMedGoogle Scholar
• Harris AG, Wilson JE, Danon SJ, Dixon MF, Donegan K, Hazell SL. Catalase (KatA) and KatA-associated protein (KapA) are essential to persistent colonization in the Helicobacter pylori SS1 mouse model. Microbiology. 2003;149(Pt 3):665–672. doi:10.1099/mic.0.26012-0
   PubMedGoogle Scholar
• Basu M, Czinn SJ, Blanchard TG. Absence of catalase reduces long-term survival of Helicobacter pylori in macrophage phagosomes. Helicobacter. 2004;9(3):211–216. doi:10.1111/j.1083-4389.2004.00226.x
   PubMed Web of Science ®Google Scholar
• Harris AG, Hinds FE, Beckhouse AG, Kolesnikow T, Hazell SL. Resistance to hydrogen peroxide in Helicobacter pylori: role of catalase (KatA) and Fur, and functional analysis of a novel gene product designated ‘KatA-associated protein’, KapA (HP0874). Microbiology. 2002;148(Pt 12):3813–3825. doi:10.1099/00221287-148-12-3813
   PubMedGoogle Scholar
• Manoochehr M, Neissi N, Tarighi P, Makvandi K, Rashidi N. Evaluation of the genes expression related to the immune system in response to Helicobacter pylori catalase epitopes. Mol Genet Microbiol Virol. 2020;35(1):47–51. doi:10.3103/S089141682001005X
   Web of Science ®Google Scholar
• Xie W, Zhao W, Zou Z, Kong L, Yang L. Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL / 6 mice. Helicobacter. 2021;26(3):e12807. doi:10.1111/hel.12807
   PubMed Web of Science ®Google Scholar
• Evans DG, Karjalainen TK, Evans DJ, Graham DY, Lee CH. Cloning, nucleotide sequence, and expression of a gene encoding an adhesin subunit protein of Helicobacter pylori. J Bacteriol. 1993;175(3):674–683. doi:10.1128/jb.175.3.674-683.1993
   PubMed Web of Science ®Google Scholar
• Sutton P, Doidge C, Pinczower G, et al. Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background. FEMS Immunol Med Microbiol. 2007;50(2):213–219. doi:10.1111/j.1574-695X.2006.00206.x
   PubMedGoogle Scholar
• Lundström AM, Blom K, Sundaeus V, Bölin I. HpaA shows variable surface localization but the gene expression is similar in different Helicobacter pylori strains. Microb Pathog. 2001;31(5):243–253. doi:10.1006/mpat.2001.0466
   PubMed Web of Science ®Google Scholar
• Odenbreit S. Adherence properties of Helicobacter pylori: impact on pathogenesis and adaptation to the host. Int J Med Microbiol. 2005;295(5):317–324. doi:10.1016/j.ijmm.2005.06.003
   PubMed Web of Science ®Google Scholar
• Peek RM, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol. 2006;208(2):233–248. doi:10.1002/path.1868
   PubMed Web of Science ®Google Scholar
• Banga Ndzouboukou JL, Lei Q, Ullah N, Zhang Y, Hao L, Fan X. Helicobacter pylori adhesins: hpaA a potential antigen in experimental vaccines for H. pylori. Helicobacter. 2021;26(1):e12758. doi:10.1111/hel.12758
   PubMed Web of Science ®Google Scholar
• Lindgren A, Pavlovic V, Flach CF, Sjöling A, Lundin S. Interferon-gamma secretion is induced in IL-12 stimulated human NK cells by recognition of Helicobacter pylori or TLR2 ligands. Innate Immun. 2011;17(2):191–203. doi:10.1177/1753425909357970
   PubMed Web of Science ®Google Scholar
• Xue RY, Guo MF, Guo L, et al. Synthetic lipopeptide enhances protective immunity against Helicobacter pylori infection. Front Immunol. 2019;10:1372. doi:10.3389/fimmu.2019.01372
   PubMed Web of Science ®Google Scholar
• Tonello F, Dundon WG, Satin B, et al. The Helicobacter pylori neutrophil-activating protein is an iron-binding protein with dodecameric structure. Mol Microbiol. 1999;34(2):238–246. doi:10.1046/j.1365-2958.1999.01584.x
   PubMed Web of Science ®Google Scholar
• Namavar F, Sparrius M, Veerman EC, Appelmelk BJ, Vandenbroucke-Grauls CM. Neutrophil-activating protein mediates adhesion of Helicobacter pylori to sulfated carbohydrates on high-molecular-weight salivary mucin. Infect Immun. 1998;66(2):444–447. doi:10.1128/IAI.66.2.444-447.1998
   PubMed Web of Science ®Google Scholar
• Brisslert M, Enarsson K, Lundin S, et al. Helicobacter pylori induce neutrophil transendothelial migration: role of the bacterial HP-NAP. FEMS Microbiol Lett. 2005;249(1):95–103. doi:10.1016/j.femsle.2005.06.008
   PubMed Web of Science ®Google Scholar
• Teneberg S, Miller-Podraza H, Lampert HC, et al. Carbohydrate binding specificity of the neutrophil-activating protein of Helicobacter pylori. J Biol Chem. 1997;272(30):19067–19071. doi:10.1074/jbc.272.30.19067
   PubMed Web of Science ®Google Scholar
• Wang G, Hong Y, Olczak A, Maier SE, Maier RJ. Dual Roles of Helicobacter pylori NapA in inducing and combating oxidative stress. Infect Immun. 2006;74(12):6839–6846. doi:10.1128/IAI.00991-06
   PubMed Web of Science ®Google Scholar
• Evans DJ, Evans DG, Takemura T, et al. Characterization of a Helicobacter pylori neutrophil-activating protein. Infect Immun. 1995;63(6):2213–2220. doi:10.1128/iai.63.6.2213-2220.1995
   PubMed Web of Science ®Google Scholar
• Satin B, Del Giudice G, Della Bianca V, et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med. 2000;191(9):1467–1476. doi:10.1084/jem.191.9.1467
   PubMed Web of Science ®Google Scholar
• Liu M, Zhong Y, Chen J, et al. Oral immunization of mice with a multivalent therapeutic subunit vaccine protects against Helicobacter pylori infection. Vaccine. 2020;38(14):3031–3041. doi:10.1016/j.vaccine.2020.02.036
   PubMed Web of Science ®Google Scholar
• Zhong Y, Chen J, Liu Y, et al. Oral immunization of BALB/c mice with recombinant Helicobacter pylori antigens and double mutant heat-labile toxin (dmLT) induces prophylactic protective immunity against H. pylori infection. Microb Pathog. 2020;145:104229. doi:10.1016/j.micpath.2020.104229
   PubMed Web of Science ®Google Scholar
• Jafari E, Mahmoodi S. Design, expression, and purification of a multi-epitope vaccine against Helicobacter Pylori based on Melittin as an adjuvant. Microb Pathog. 2021;157:104970. doi:10.1016/j.micpath.2021.104970
   PubMed Web of Science ®Google Scholar
• Yamaoka Y, Kwon DH, Graham DY. A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci U S A. 2000;97(13):7533–7538. doi:10.1073/pnas.130079797
   PubMed Web of Science ®Google Scholar
• Tabassam FH, Graham DY, Yamaoka Y. OipA plays a role in Helicobacter pylori-induced focal adhesion kinase activation and cytoskeletal re-organization. Cell Microbiol. 2008;10(4):1008–1020. doi:10.1111/j.1462-5822.2007.01104.x
   PubMed Web of Science ®Google Scholar
• Dossumbekova A, Prinz C, Mages J, et al. Helicobacter pylori HopH (OipA) and bacterial pathogenicity: genetic and functional genomic analysis of hopH gene polymorphisms. J Infect Dis. 2006;194(10):1346–1355. doi:10.1086/508426
   PubMed Web of Science ®Google Scholar
• Soudi H, Falsafi T, Mahboubi M, Gharavi S. Evaluation of Helicobacter pylori OipA protein as a vaccine candidate and propolis as an adjuvant in C57BL/6 mice. Iran J Basic Med Sci. 2021;24(9):1220–1230. doi:10.22038/ijbms.2021.56232.12579
   PubMed Web of Science ®Google Scholar
• Mittl PR, Lüthy L, Reinhardt C, Joller H. Detection of high titers of antibody against Helicobacter cysteine-rich proteins A, B, C, and E in Helicobacter pylori-infected individuals. Clin Diagn Lab Immunol. 2003;10(4):542–545. doi:10.1128/cdli.10.4.542-545.2003
   PubMedGoogle Scholar
• Krishnamurthy P, Parlow MH, Schneider J, et al. Identification of a novel penicillin-binding protein from Helicobacter pylori. J Bacteriol. 1999;181(16):5107–5110. doi:10.1128/JB.181.16.5107-5110.1999
   PubMed Web of Science ®Google Scholar
• Nasr-Esfahani M, Doosti A, Jami MS. Chitosan nanoparticles-mediated pCDNA3.1(–)-hcpD DNA vaccine against Helicobacter pylori in BALB/c mice. Mol Genet Microbiol Virol. 2019;34(2):131–139. doi:10.3103/S0891416819020083
   Web of Science ®Google Scholar
• Eaton KA, Suerbaum S, Josenhans C, Krakowka S. Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes. Infect Immun. 1996;64(7):2445–2448. doi:10.1128/iai.64.7.2445-2448.1996
   PubMed Web of Science ®Google Scholar
• Kostrzynska M, Betts JD, Austin JW, Trust TJ. Identification, characterization, and spatial localization of two flagellin species in Helicobacter pylori flagella. J Bacteriol. 1991;173(3):937–946. doi:10.1128/jb.173.3.937-946.1991
   PubMed Web of Science ®Google Scholar
• Yan J, Liang SH, Mao YF, Li LW, Li SP. Construction of expression systems for flaA and flaB genes of Helicobacter pylori and determination of immunoreactivity and antigenicity of recombinant proteins. World J Gastroenterol. 2003;9(10):2240–2250. doi:10.3748/wjg.v9.i10.2240
   PubMed Web of Science ®Google Scholar
• Gu H. Role of flagella in the pathogenesis of Helicobacter pylori. Curr Microbiol. 2017;74(7):863–869. doi:10.1007/s00284-017-1256-4
   PubMed Web of Science ®Google Scholar
• Ansari H, Tahmasebi-Birgani M, Bijanzadeh M. DNA vaccine containing Flagellin A gene induces significant immune responses against Helicobacter pylori infection: an in vivo study. Iran J Basic Med Sci. 2021;24(6):796–804. doi:10.22038/ijbms.2021.54415.12227
   PubMed Web of Science ®Google Scholar
• Hamzehloo Z, Mosayebi G, Khansarinejad B, Zolfaghari M, Abtahi H. Antigenicity identification of a novel recombinant multi-epitope antigen based on FlaA and UreB antigens of Helicobacter pylori. Jundishapur J Microbiol. 2019. doi:10.5812/jjm.66502
   Web of Science ®Google Scholar
• Kim JS, Chang JH, Chung SI, Yum JS. Molecular cloning and characterization of the Helicobacter pylori fliD gene, an essential factor in flagellar structure and motility. J Bacteriol. 1999;181(22):6969–6976. doi:10.1128/JB.181.22.6969-6976.1999
   PubMed Web of Science ®Google Scholar
• Tasteyre A, Barc MC, Collignon A, Boureau H, Karjalainen T. Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect Immun. 2001;69(12):7937–7940. doi:10.1128/IAI.69.12.7937-7940.2001
   PubMed Web of Science ®Google Scholar
• Cho SY, Song WS, Oh HB, Kim HU, Jung HS, Yoon SI. Structural analysis of the flagellar capping protein FliD from Helicobacter pylori. Biochem Biophys Res Commun. 2019;514(1):98–104. doi:10.1016/j.bbrc.2019.04.065
   PubMed Web of Science ®Google Scholar
• Ghasemi A, Mohammad N, Mautner J, Karsabet MT, Ardjmand A, Moniri R. Immunization with recombinant FliD confers protection against Helicobacter pylori infection in mice. Mol Immunol. 2018;94:176–182. doi:10.1016/j.molimm.2018.01.001
   PubMed Web of Science ®Google Scholar
• Monteiro MA, Britton S, Applebee LA, Baqar S. Synthesis and immunogenicity of a Helicobacter pylori lipopolysaccharide-based conjugate. Vaccine. 2011;29(17):3098–3102. doi:10.1016/j.vaccine.2011.02.063
   PubMed Web of Science ®Google Scholar
• Yokota S, Okabayashi T, Rehli M, Fujii N, Amano K. Helicobacter pylori lipopolysaccharides upregulate toll-like receptor 4 expression and proliferation of gastric epithelial cells via the MEK1/2-ERK1/2 mitogen-activated protein kinase pathway. Infect Immun. 2010;78(1):468–476. doi:10.1128/IAI.00903-09
   PubMed Web of Science ®Google Scholar
• Monteiro MA. Helicobacter pylori: a wolf in sheep’s clothing: the glycotype families of Helicobacter pylori lipopolysaccharides expressing histo-blood groups: structure, biosynthesis, and role in pathogenesis. Adv Carbohydr Chem Biochem. 2001;57:99–158.
   PubMed Web of Science ®Google Scholar
• Eaton KA, Logan SM, Baker PE, Peterson RA, Monteiro MA, Altman E. Helicobacter pylori with a truncated lipopolysaccharide O chain fails to induce gastritis in SCID mice injected with splenocytes from wild-type C57BL/6J mice. Infect Immun. 2004;72(7):3925–3931. doi:10.1128/IAI.72.7.3925-3931.2004
   PubMed Web of Science ®Google Scholar
• Tian G, Qin C, Liu Z, et al. Total synthesis of the Helicobacter pylori serotype O2 O-antigen alpha-(1 --> 2)- and alpha-(1 --> 3)-linked oligoglucosides. Chem Commun (Camb). 2020;56(3):344–347. doi:10.1039/C9CC07915G
   PubMed Web of Science ®Google Scholar
• Kostrzynska M, O’Toole PW, Taylor DE, Trust TJ. Molecular characterization of a conserved 20-kilodalton membrane-associated lipoprotein antigen of Helicobacter pylori. J Bacteriol. 1994;176(19):5938–5948. doi:10.1128/jb.176.19.5938-5948.1994
   PubMed Web of Science ®Google Scholar
• Keenan J, Oliaro J, Domigan N, et al. Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate. Infect Immun. 2000;68(6):3337–3343. doi:10.1128/IAI.68.6.3337-3343.2000
   PubMed Web of Science ®Google Scholar
• Cao P, McClain MS, Forsyth MH, Cover TL. Extracellular release of antigenic proteins by Helicobacter pylori. Infect Immun. 1998;66(6):2984–2986. doi:10.1128/IAI.66.6.2984-2986.1998
   PubMed Web of Science ®Google Scholar
• Hocking D, Webb E, Radcliff F, et al. Isolation of recombinant protective Helicobacter pylori antigens. Infect Immun. 1999;67(9):4713–4719. doi:10.1128/IAI.67.9.4713-4719.1999
   PubMed Web of Science ®Google Scholar
• Ning Y, Ye J, Wen J, et al. Identification of two Lpp20 CD4+ T cell epitopes in Helicobacter pylori-infected subjects. Front Microbiol. 2018;9:884. doi:10.3389/fmicb.2018.00884
   PubMed Web of Science ®Google Scholar
• Sun N, Zhang R, Duan G, et al. A food-grade engineered Lactococcus lactis strain delivering Helicobacter pylori Lpp20 alleviates bacterial infection in H. pylori-challenged mice. Biotechnol Lett. 2019;41(12):1415–1421. doi:10.1007/s10529-019-02740-z
   PubMed Web of Science ®Google Scholar
• Suerbaum S, Thiberge JM, Kansau I, Ferrero RL, Labigne A. Helicobacter pylori hspA-hspB heat-shock gene cluster: nucleotide sequence, expression, putative function and immunogenicity. Mol Microbiol. 1994;14(5):959–974. doi:10.1111/j.1365-2958.1994.tb01331.x
   PubMed Web of Science ®Google Scholar
• Kansau I, Guillain F, Thiberge JM, Labigne A. Nickel binding and immunological properties of the C-terminal domain of the Helicobacter pylori GroES homologue (HspA). Mol Microbiol. 1996;22(5):1013–1023. doi:10.1046/j.1365-2958.1996.01536.x
   PubMed Web of Science ®Google Scholar
• Cun S, Li H, Ge R, Lin MC, Sun H. A histidine-rich and cysteine-rich metal-binding domain at the C terminus of heat shock protein A from Helicobacter pylori: implication for nickel homeostasis and bismuth susceptibility. J Biol Chem. 2008;283(22):15142–15151. doi:10.1074/jbc.M800591200
   PubMed Web of Science ®Google Scholar
• Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci U S A. 1995;92(14):6499–6503. doi:10.1073/pnas.92.14.6499
   PubMed Web of Science ®Google Scholar
• Wu C, Shi Y, Guo H, et al. Protection against Helicobacter pylori infection in Mongolian gerbil by intragastric or intramuscular administration of H. pylori multicomponent vaccine. Helicobacter. 2008;13(3):191–199. doi:10.1111/j.1523-5378.2008.00609.x
   PubMed Web of Science ®Google Scholar
• Zhang X, Sang S, Guan Q, Tao H, Wang Y, Liu C. Identification of B-cell epitopes of HspA from Helicobacter pylori and detection of epitope antibody profiles in naturally infected persons. Vaccines. 2021;10(1). doi:10.3390/vaccines10010065
   Web of Science ®Google Scholar
• Iankov ID, Kurokawa C, Viker K, et al. Live attenuated measles virus vaccine expressing Helicobacter pylori heat shock protein A. Mol Ther Oncolytics. 2020;19:136–148. doi:10.1016/j.omto.2020.09.006
   PubMed Web of Science ®Google Scholar
• González-López MA, Velázquez-Guadarrama N, Romero-Espejel ME, Olivares-Trejo Jde J. Helicobacter pylori secretes the chaperonin GroEL (HSP60), which binds iron. FEBS Lett. 2013;587(12):1823–1828. doi:10.1016/j.febslet.2013.04.048
   PubMed Web of Science ®Google Scholar
• Gao L, Michel A, Weck MN, Arndt V, Pawlita M, Brenner H. Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res. 2009;69(15):6164–6170. doi:10.1158/0008-5472.CAN-09-0596
   PubMed Web of Science ®Google Scholar
• Gao L, Weck MN, Michel A, Pawlita M, Brenner H. Association between chronic atrophic gastritis and serum antibodies to 15 Helicobacter pylori proteins measured by multiplex serology. Cancer Res. 2009;69(7):2973–2980. doi:10.1158/0008-5472.CAN-08-3477
   PubMed Web of Science ®Google Scholar
• Macchia G, Massone A, Burroni D, Covacci A, Censini S, Rappuoli R. The Hsp60 protein of Helicobacter pylori: structure and immune response in patients with gastroduodenal diseases. Mol Microbiol. 1993;9(3):645–652. doi:10.1111/j.1365-2958.1993.tb01724.x
   PubMed Web of Science ®Google Scholar
• Khan M, Khan S, Ali A, et al. Immunoinformatics approaches to explore Helicobacter Pylori proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine. Sci Rep. 2019;9(1):13321. doi:10.1038/s41598-019-49354-z
   PubMedGoogle Scholar
• Espinosa-Ramos D, Caballero-Hernandez D, Gomez-Flores R, et al. Immunization with a synthetic Helicobacter pylori peptide induces secretory IgA antibodies and protects mice against infection. Can J Infect Dis Med Microbiol. 2019;2019:8595487. doi:10.1155/2019/8595487
   PubMed Web of Science ®Google Scholar
• Merritt EA, Zhang Z, Pickens JC, Ahn M, Hol WG, Fan E. Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat-labile enterotoxin. J Am Chem Soc. 2002;124(30):8818–8824. doi:10.1021/ja0202560
   PubMed Web of Science ®Google Scholar
• Clements JD, Hartzog NM, Lyon FL. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine. 1988;6(3):269–277. doi:10.1016/0264-410X(88)90223-X
   PubMed Web of Science ®Google Scholar
• Clements JD, Yancey RJ, Finkelstein RA. Properties of homogeneous heat-labile enterotoxin from Escherichia coli. Infect Immun. 1980;29(1):91–97. doi:10.1128/iai.29.1.91-97.1980
   PubMed Web of Science ®Google Scholar
• Ma Y, Luo Y, Huang X, Song F, Liu G. Construction of Bifidobacterium infantis as a live oral vaccine that expresses antigens of the major fimbrial subunit (CfaB) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic Escherichia coli. Microbiology. 2012;158(Pt 2):498–504. doi:10.1099/mic.0.049932-0
   PubMedGoogle Scholar
• Jeon BW, Nandre RM, Lee JH. Oral immunization with an attenuated Salmonella Gallinarum mutant as a fowl typhoid vaccine with a live adjuvant strain secreting the B subunit of Escherichia coli heat-labile enterotoxin. BMC Vet Res. 2013;9:96. doi:10.1186/1746-6148-9-96
   PubMed Web of Science ®Google Scholar
• Chaudhari AA, Lee JH. Evaluation of the adjuvant effect of Salmonella-based Escherichia coli heat-labile toxin B subunits on the efficacy of a live Salmonella-delivered avian pathogenic Escherichia coli vaccine. Avian Pathol. 2013;42(4):365–372. doi:10.1080/03079457.2013.811466
   PubMed Web of Science ®Google Scholar
• Peng X, Zhang R, Wang C, et al. E. coli enterotoxin LtB enhances vaccine-induced anti-H. pylori protection by promoting leukocyte migration into gastric mucus via inflammatory lesions. Cells. 2019;8(9). doi:10.3390/cells8090982
   Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, et al. A toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740–745. doi:10.1038/35047123
   PubMed Web of Science ®Google Scholar
• Klinman DM, Conover J, Coban C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun. 1999;67(11):5658–5663. doi:10.1128/IAI.67.11.5658-5663.1999
   PubMed Web of Science ®Google Scholar
• Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 1998;282(5388):476–480. doi:10.1126/science.282.5388.476
   PubMed Web of Science ®Google Scholar
• Klinman DM. Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opin Biol Ther. 2004;4(6):937–946. doi:10.1517/14712598.4.6.937
   PubMed Web of Science ®Google Scholar
• Kato K, Omura H, Ishitani R, Nureki O. Cyclic GMP-AMP as an endogenous second messenger in innate immune signaling by cytosolic DNA. Annu Rev Biochem. 2017;86:541–566. doi:10.1146/annurev-biochem-061516-044813
   PubMed Web of Science ®Google Scholar
• Corrales L, Glickman LH, McWhirter SM, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11(7):1018–1030. doi:10.1016/j.celrep.2015.04.031
   PubMed Web of Science ®Google Scholar
• Li XD, Wu J, Gao D, Wang H, Sun L, Chen ZJ. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science. 2013;341(6152):1390–1394. doi:10.1126/science.1244040
   PubMed Web of Science ®Google Scholar
• Kranzusch PJ, Wilson SC, Lee AS, Berger JM, Doudna JA, Vance RE. Ancient origin of cGAS-STING reveals mechanism of universal 2’,3’ cGAMP signaling. Mol Cell. 2015;59(6):891–903. doi:10.1016/j.molcel.2015.07.022
   PubMed Web of Science ®Google Scholar
• Chen J, Zhong Y, Liu Y, et al. Parenteral immunization with a cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) adjuvanted Helicobacter pylori vaccine induces protective immunity against H. pylori infection in mice. Hum Vaccin Immunother. 2020;16(11):2849–2854. doi:10.1080/21645515.2020.1744364
   PubMed Web of Science ®Google Scholar
• Wang H, Liu YM, Qi ZM, et al. An overview on natural polysaccharides with antioxidant properties. Curr Med Chem. 2013;20(23):2899–2913. doi:10.2174/0929867311320230006
   PubMed Web of Science ®Google Scholar
• Pi CC, Chu CL, Lu CY, et al. Polysaccharides from Ganoderma formosanum function as a Th1 adjuvant and stimulate cytotoxic T cell response in vivo. Vaccine. 2014;32(3):401–408. doi:10.1016/j.vaccine.2013.11.027
   PubMed Web of Science ®Google Scholar
• Yang L, Hu Y, Xue J, et al. Compound Chinese herbal medicinal ingredients can enhance immune response and efficacy of RHD vaccine in rabbit. Vaccine. 2008;26(35):4451–4455. doi:10.1016/j.vaccine.2008.06.075
   PubMed Web of Science ®Google Scholar
• Qiu Y, Hu YL, Cui BA, et al. Immunopotentiating effects of four Chinese herbal polysaccharides administered at vaccination in chickens. Poult Sci. 2007;86(12):2530–2535. doi:10.3382/ps.2007-00076
   PubMed Web of Science ®Google Scholar
• Chen Z, Lu J, Srinivasan N, Tan BK, Chan SH. Polysaccharide-protein complex from Lycium barbarum L. is a novel stimulus of dendritic cell immunogenicity. J Immunol. 2009;182(6):3503–3509. doi:10.4049/jimmunol.0802567
   PubMed Web of Science ®Google Scholar
• Liu C, Luo J, Xue RY, et al. The mucosal adjuvant effect of plant polysaccharides for induction of protective immunity against Helicobacter pylori infection. Vaccine. 2019;37(8):1053–1061. doi:10.1016/j.vaccine.2018.12.066
   PubMed Web of Science ®Google Scholar
• Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997;278(5343):1626–1629. doi:10.1126/science.278.5343.1626
   PubMed Web of Science ®Google Scholar
• Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol. 2005;175(5):3309–3317. doi:10.4049/jimmunol.175.5.3309
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med. 2002;195(5):617–624. doi:10.1084/jem.20011889
   PubMed Web of Science ®Google Scholar
• Longet S, Abautret-Daly A, Davitt CJH, et al. An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R- and IL-17R-dependent Th1 responses. NPJ Vaccines. 2019;4:45. doi:10.1038/s41541-019-0139-z
   PubMed Web of Science ®Google Scholar
• Thompson AL, Staats HF. Cytokines: the future of intranasal vaccine adjuvants. Clin Dev Immunol. 2011;2011:289597. doi:10.1155/2011/289597
   PubMedGoogle Scholar
• Nemattalab M, Shenagari M, Taheri M, et al. Co-expression of Interleukin-17A molecular adjuvant and prophylactic Helicobacter pylori genetic vaccine could cause sterile immunity in Treg suppressed mice. Cytokine. 2020;126:154866. doi:10.1016/j.cyto.2019.154866
   PubMed Web of Science ®Google Scholar
• Touzani S, Embaslat W, Imtara H, et al. In vitro evaluation of the potential use of propolis as a multitarget therapeutic product: physicochemical properties, chemical composition, and immunomodulatory, antibacterial, and anticancer properties. Biomed Res Int. 2019;2019:4836378. doi:10.1155/2019/4836378
   PubMed Web of Science ®Google Scholar
• Fischer G, Conceição FR, Leite FP, et al. Immunomodulation produced by a green propolis extract on humoral and cellular responses of mice immunized with SuHV-1. Vaccine. 2007;25(7):1250–1256. doi:10.1016/j.vaccine.2006.10.005
   PubMed Web of Science ®Google Scholar
• Fischer G, Paulino N, Marcucci MC, et al. Green propolis phenolic compounds act as vaccine adjuvants, improving humoral and cellular responses in mice inoculated with inactivated vaccines. Mem Inst Oswaldo Cruz. 2010;105(7):908–913. doi:10.1590/S0074-02762010000700012
   PubMed Web of Science ®Google Scholar
• Chen W, Kuolee R, Yan H. The potential of 3’,5’-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant. Vaccine. 2010;28(18):3080–3085. doi:10.1016/j.vaccine.2010.02.081
   PubMed Web of Science ®Google Scholar
• Karaolis DK, Means TK, Yang D, et al. Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol. 2007;178(4):2171–2181. doi:10.4049/jimmunol.178.4.2171
   PubMed Web of Science ®Google Scholar
• Quartermain MD, Pasquali SK, Hill KD, et al. Variation in prenatal diagnosis of congenital heart disease in infants. Pediatrics. 2015;136(2):e378–385. doi:10.1542/peds.2014-3783
   PubMed Web of Science ®Google Scholar
• Li J, Lee RK, Chen W, Yan H. 2′-fluoro-c-di-GMP as an oral vaccine adjuvant. RSC Adv. 2019;9(71):41481–41489. doi:10.1039/C9RA08310C
   PubMed Web of Science ®Google Scholar
• Wang S, Ma J, Ji Q, Liu Q. Evaluation of an attenuated Listeria monocytogenes as a vaccine vector to control Helicobacter pylori infection. Immunol Lett. 2021;238:68–74. doi:10.1016/j.imlet.2021.07.010
   PubMed Web of Science ®Google Scholar
• Wells JM, Robinson K, Chamberlain LM, Schofield KM, Le Page RWF. Lactic acid bacteria as vaccine delivery vehicles. Antonie van Leeuwenhoek. 1996;70(2):317–330. doi:10.1007/BF00395939
   PubMed Web of Science ®Google Scholar
• Cano-Garrido O, Seras-Franzoso J, Garcia-Fruitós E. Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes. Microb Cell Fact. 2015;14:137. doi:10.1186/s12934-015-0313-6
   PubMed Web of Science ®Google Scholar
• Hongying F, Xianbo W, Fang Y, Yang B, Beiguo L. Oral immunization with recombinant Lactobacillus acidophilus expressing the adhesin Hp0410 of Helicobacter pylori induces mucosal and systemic immune responses. Clin Vaccine Immunol. 2014;21(2):126–132. doi:10.1128/CVI.00434-13
   PubMedGoogle Scholar
• Guo L, Zhang F, Wang S, et al. Oral immunization with a M cell-targeting recombinant L. lactis vaccine LL-plSAM-FVpE stimulate protective immunity against H. pylori in mice. Front Immunol. 2022;13:918160. doi:10.3389/fimmu.2022.918160
   PubMed Web of Science ®Google Scholar
• Darby RA, Cartwright SP, Dilworth MV, Bill RM. Which yeast species shall I choose? Saccharomyces cerevisiae versus Pichia pastoris (review). Methods Mol Biol. 2012;866:11–23.
   PubMedGoogle Scholar
• Kumar R, Kumar P. Yeast-based vaccines: new perspective in vaccine development and application. FEMS Yeast Res. 2019;19(2). doi:10.1093/femsyr/foz007
   Web of Science ®Google Scholar
• Cen Q, Gao T, Ren Y, Lu X, Lei H. Immune evaluation of a Saccharomyces cerevisiae-based oral vaccine against Helicobacter pylori in mice. Helicobacter. 2021;26(1):e12772. doi:10.1111/hel.12772
   PubMed Web of Science ®Google Scholar
• Rothman J, Paterson Y. Live-attenuated Listeria-based immunotherapy. Expert Rev Vaccines. 2013;12(5):493–504. doi:10.1586/erv.13.34
   PubMed Web of Science ®Google Scholar
• Venkatesan M, Fernandez-Prada C, Buysse JM, Formal SB, Hale TL. Virulence phenotype and genetic characteristics of the T32-ISTRATI Shigella flexneri 2a vaccine strain. Vaccine. 1991;9(5):358–363. doi:10.1016/0264-410X(91)90064-D
   PubMed Web of Science ®Google Scholar
• Zhang X, Sang S, Guan Q, Tao H, Wang Y, Liu C. Oral administration of a Shigella 2aT32-based vaccine expressing UreB-HspA fusion antigen with and without parenteral rUreB-HspA boost confers protection against Helicobacter pylori in mice model. Front Immunol. 2022;13:894206. doi:10.3389/fimmu.2022.894206
   PubMed Web of Science ®Google Scholar
• Tan Z, Liu W, Liu H, et al. Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection. Eur J Pharm Biopharm. 2017;111:33–43. doi:10.1016/j.ejpb.2016.11.007
   PubMed Web of Science ®Google Scholar
• Francis JE, Skakic I, Dekiwadia C, et al. Solid lipid nanoparticle carrier platform containing synthetic TLR4 agonist mediates non-viral DNA vaccine delivery. Vaccines. 2020;8(3). doi:10.3390/vaccines8030551
   Web of Science ®Google Scholar
• Lim M, Badruddoza AZM, Firdous J, et al. Engineered nanodelivery systems to improve DNA vaccine technologies. Pharmaceutics. 2020;12(1):30. doi:10.3390/pharmaceutics12010030
   PubMed Web of Science ®Google Scholar
• Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine. 2004;22(19):2406–2412. doi:10.1016/j.vaccine.2003.12.032
   PubMed Web of Science ®Google Scholar
• Bondi ML, Azzolina A, Craparo EF, et al. Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery. J Drug Target. 2007;15(4):295–301. doi:10.1080/10611860701324698
   PubMed Web of Science ®Google Scholar
• Penumarthi A, Parashar D, Abraham AN, et al. Solid lipid nanoparticles mediate non-viral delivery of plasmid DNA to dendritic cells. J Nanopart Res. 2017;19(6). doi:10.1007/s11051-017-3902-y
   Web of Science ®Google Scholar
• Kim HR, Kim IK, Bae KH, Lee SH, Lee Y, Park TG. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol Pharm. 2008;5(4):622–631. doi:10.1021/mp8000233
   PubMedGoogle Scholar
• Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin Immunol. 2018;39:14–21. doi:10.1016/j.smim.2018.05.001
   PubMed Web of Science ®Google Scholar
• Wagner R, Hildt E. Composition and mode of action of adjuvants in licensed viral vaccines. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019;62(4):462–471. doi:10.1007/s00103-019-02921-1
   PubMed Web of Science ®Google Scholar
• Zhdanov VM. The measles virus. Mol Cell Biochem. 1980;29(1):59–66. doi:10.1007/BF00230955
   PubMed Web of Science ®Google Scholar
• Zuniga A, Wang Z, Liniger M, et al. Attenuated measles virus as a vaccine vector. Vaccine. 2007;25(16):2974–2983. doi:10.1016/j.vaccine.2007.01.064
   PubMed Web of Science ®Google Scholar
• Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotechnol J. 2010;8(5):620–637. doi:10.1111/j.1467-7652.2010.00507.x
   PubMed Web of Science ®Google Scholar
• Abdoli-nasab M, Torabi-nia N. Transient expression of UreB of Helicobacter pylori in spinach (Spinacia oleracea). Sci Hortic (Amsterdam). 2019;247:320–326. doi:10.1016/j.scienta.2018.12.018
   Web of Science ®Google Scholar
• Roier S, Zingl FG, Cakar F, et al. A novel mechanism for the biogenesis of outer membrane vesicles in Gram-negative bacteria. Nat Commun. 2016;7:10515. doi:10.1038/ncomms10515
   PubMed Web of Science ®Google Scholar
• Beveridge TJ. Structures of gram-negative cell walls and their derived membrane vesicles. J Bacteriol. 1999;181(16):4725–4733. doi:10.1128/JB.181.16.4725-4733.1999
   PubMed Web of Science ®Google Scholar
• Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol. 2022;53(1):33–50. doi:10.1007/s42770-021-00675-0
   PubMed Web of Science ®Google Scholar
• Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol. 2015;13(10):605–619. doi:10.1038/nrmicro3525
   PubMed Web of Science ®Google Scholar
• Chen DJ, Osterrieder N, Metzger SM, et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci U S A. 2010;107(7):3099–3104. doi:10.1073/pnas.0805532107
   PubMed Web of Science ®Google Scholar
• Chmiela M, Walczak N, Rudnicka K. Helicobacter pylori outer membrane vesicles involvement in the infection development and Helicobacter pylori-related diseases. J Biomed Sci. 2018;25(1):78. doi:10.1186/s12929-018-0480-y
   PubMedGoogle Scholar
• Liu Q, Li X, Zhang Y, et al. Orally-administered outer-membrane vesicles from Helicobacter pylori reduce H. pylori infection via Th2-biased immune responses in mice. Pathog Dis. 2019;77(5). doi:10.1093/femspd/ftz050
   Web of Science ®Google Scholar
• Robinson K, Kenefeck R, Pidgeon EL, et al. Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut. 2008;57(10):1375–1385. doi:10.1136/gut.2007.137539
   PubMed Web of Science ®Google Scholar
• Oertli M, Noben M, Engler DB, et al. Helicobacter pylori γ-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci U S A. 2013;110(8):3047–3052. doi:10.1073/pnas.1211248110
   PubMed Web of Science ®Google Scholar
• Israel DA, Salama N, Krishna U, et al. Helicobacter pylori genetic diversity within the gastric niche of a single human host. Proc Natl Acad Sci U S A. 2001;98(25):14625–14630. doi:10.1073/pnas.251551698
   PubMed Web of Science ®Google Scholar
• Amieva MR, Salama NR, Tompkins LS, Falkow S. Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells. Cell Microbiol. 2002;4(10):677–690. doi:10.1046/j.1462-5822.2002.00222.x
   PubMed Web of Science ®Google Scholar
• Necchi V, Candusso ME, Tava F, et al. Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori. Gastroenterology. 2007;132(3):1009–1023. doi:10.1053/j.gastro.2007.01.049
   PubMed Web of Science ®Google Scholar
• Semino-Mora C, Doi SQ, Marty A, Simko V, Carlstedt I, Dubois A. Intracellular and interstitial expression of Helicobacter pylori virulence genes in gastric precancerous intestinal metaplasia and adenocarcinoma. J Infect Dis. 2003;187(8):1165–1177. doi:10.1086/368133
   PubMed Web of Science ®Google Scholar
• Engstrand L, Graham D, Scheynius A, Genta RM, El-Zaatari F. Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular? Am J Clin Pathol. 1997;108(5):504–509. doi:10.1093/ajcp/108.5.504
   PubMed Web of Science ®Google Scholar
• Dubois A, Borén T. Helicobacter pylori is invasive and it may be a facultative intracellular organism. Cell Microbiol. 2007;9(5):1108–1116. doi:10.1111/j.1462-5822.2007.00921.x
   PubMed Web of Science ®Google Scholar
• Solnick JV, Canfield DR, Hansen LM, Torabian SZ. Immunization with recombinant Helicobacter pylori urease in specific-pathogen-free rhesus monkeys (Macaca mulatta). Infect Immun. 2000;68(5):2560–2565. doi:10.1128/IAI.68.5.2560-2565.2000
   PubMed Web of Science ®Google Scholar
• Dubois A, Fiala N, Heman-Ackah LM, et al. Natural gastric infection with Helicobacter pylori in monkeys: a model for spiral bacteria infection in humans. Gastroenterology. 1994;106(6):1405–1417. doi:10.1016/0016-5085(94)90392-1
   PubMed Web of Science ®Google Scholar
• Solnick JV, Canfield DR, Yang S, Parsonnet J. Rhesus monkey (Macaca mulatta) model of Helicobacter pylori: noninvasive detection and derivation of specific-pathogen-free monkeys. Lab Anim Sci. 1999;49(2):197–201.
   PubMedGoogle Scholar
• Calado CRC. Antigenic and conserved peptides from diverse Helicobacter pylori antigens. Biotechnol Lett. 2022;44(3):535–545. doi:10.1007/s10529-022-03238-x
   PubMed Web of Science ®Google Scholar
• Sjökvist Ottsjö L, Flach CF, Clements J, Holmgren J, Raghavan S. A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun. 2013;81(5):1532–1540. doi:10.1128/IAI.01407-12
   PubMed Web of Science ®Google Scholar
• Lindqvist M, Persson J, Thörn K, Harandi AM. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol. 2009;182(10):6435–6443. doi:10.4049/jimmunol.0900136
   PubMed Web of Science ®Google Scholar
• Wang J, Li P, Wu MX. Natural STING agonist as an “ideal” adjuvant for cutaneous vaccination. J Invest Dermatol. 2016;136(11):2183–2191. doi:10.1016/j.jid.2016.05.105
   PubMed Web of Science ®Google Scholar